Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
Rating
Sector Rating
Recommendation *
Avoid
Neutral
Fair
Quality
Rating Breakdown
Avg.
Relative Strength
The relative strength of a dividend stock indicates whether the stock is uptrending or not. The major determining factor in this rating is whether the stock is trading close to its 52-week-high.
Overall Yield Attractiveness
If a stock’s yield is above or near the market average then it will be rated higher within this parameter. High dividend yields (usually over 10%) should be considered extremely risky, while low dividend yields (1% or less) are simply not very beneficial to long-term investors.
Dividend Reliability
A stock’s dividend reliability is determined by a healthy payout ratio that is higher than other stocks. A company that pays out close to half its earnings as dividends and retains the other half of earnings has ample room to grow its business and pay out more dividends in the future.
Dividend Uptrend
A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. If a stock is valued near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase.
Earnings Growth
A stock’s Earnings Growth rating evaluates a company’s expected EPS for the current financial year and compares it to next financial year’s expected EPS. Stocks with single-digit growth estimates will have a higher rating than others, as our research has shown that well-established dividend-paying companies have modest earnings growth estimates.
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
BlackRock Future Health ETF
Active ETF
BMED
Payout Change
None
Price as of:
$22.6
+0.42
+1.89%
primary theme
Health Care Sector Equity
BMED (ETF)
BlackRock Future Health ETF
Payout Change
None
Price as of:
$22.6
+0.42
+1.89%
primary theme
Health Care Sector Equity
BMED (ETF)
BlackRock Future Health ETF
Payout Change
None
Price as of:
$22.6
+0.42
+1.89%
primary theme
Health Care Sector Equity
Name
Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
-16.0%
1 yr return
-22.1%
3 Yr Avg Return
N/A
5 Yr Avg Return
N/A
Net Assets
$7.24 M
Holdings in Top 10
26.0%
52 WEEK LOW AND HIGH
$22.2
$20.76
$31.13
Expenses
OPERATING FEES
Expense Ratio 0.85%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover N/A
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
BMED - Profile
Distributions
- YTD Total Return -21.8%
- 3 Yr Annualized Total Return N/A
- 5 Yr Annualized Total Return N/A
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.64%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameBlackRock Future Health ETF
-
Fund Family NameBlackRock
-
Inception DateSep 29, 2020
-
Shares Outstanding320000
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerXiang Liu
Fund Description
BMED - Performance
Return Ranking - Trailing
| Period | BMED Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -16.0% | -25.6% | 23.4% | 97.24% |
| 1 Yr | -22.1% | -27.6% | 26.0% | 98.20% |
| 3 Yr | N/A* | -18.9% | 19.7% | N/A |
| 5 Yr | N/A* | -15.2% | 15.3% | N/A |
| 10 Yr | N/A* | -5.7% | 16.3% | N/A |
* Annualized
Return Ranking - Calendar
| Period | BMED Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -4.0% | -53.9% | 11.7% | 10.78% |
| 2021 | N/A | -22.3% | 18.5% | N/A |
| 2020 | N/A | -4.7% | 41.4% | N/A |
| 2019 | N/A | -10.2% | 13.1% | N/A |
| 2018 | N/A | -5.7% | 26.9% | N/A |
Total Return Ranking - Trailing
| Period | BMED Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -21.8% | -41.2% | 23.4% | 97.24% |
| 1 Yr | -22.1% | -28.5% | 28.3% | 98.32% |
| 3 Yr | N/A* | -18.9% | 19.7% | N/A |
| 5 Yr | N/A* | -15.2% | 15.3% | N/A |
| 10 Yr | N/A* | -5.7% | 16.3% | N/A |
* Annualized
Total Return Ranking - Calendar
| Period | BMED Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -4.0% | -53.9% | 11.7% | 10.78% |
| 2021 | N/A | -22.3% | 18.5% | N/A |
| 2020 | N/A | -4.7% | 41.4% | N/A |
| 2019 | N/A | -10.2% | 13.1% | N/A |
| 2018 | N/A | -5.7% | 26.9% | N/A |
BMED - Holdings
Concentration Analysis
| BMED | Category Low | Category High | BMED % Rank | |
|---|---|---|---|---|
| Net Assets | 7.24 M | 732 K | 46.2 B | 87.37% |
| Number of Holdings | 134 | 3 | 507 | 17.50% |
| Net Assets in Top 10 | 1.88 M | 2.18 K | 21.6 B | 93.50% |
| Weighting of Top 10 | 25.98% | 12.3% | 100.0% | 94.00% |
Top 10 Holdings
- BlackRock Cash Funds Treasury SL Agency 4.97%
- Seattle Genetics Inc 3.76%
- Genmab A/S 3.54%
- Genmab A/S 3.54%
- Genmab A/S 3.54%
- Genmab A/S 3.54%
- Genmab A/S 3.54%
- Genmab A/S 3.54%
- Genmab A/S 3.54%
- Genmab A/S 3.54%
Asset Allocation
| Weighting | Return Low | Return High | BMED % Rank | |
|---|---|---|---|---|
| Stocks | 94.94% | 0.09% | 106.13% | 90.00% |
| Cash | 5.06% | -0.10% | 99.91% | 8.50% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 49.50% |
| Other | 0.00% | -22.99% | 3.38% | 54.50% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 49.50% |
| Bonds | 0.00% | 0.00% | 12.39% | 48.00% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | BMED % Rank | |
|---|---|---|---|---|
| Healthcare | 97.16% | 26.56% | 100.00% | 84.00% |
| Financial Services | 1.85% | 0.00% | 8.43% | 1.00% |
| Basic Materials | 0.99% | 0.00% | 14.83% | 9.00% |
| Utilities | 0.00% | 0.00% | 1.52% | 46.50% |
| Technology | 0.00% | 0.00% | 28.70% | 51.50% |
| Real Estate | 0.00% | 0.00% | 7.13% | 50.50% |
| Industrials | 0.00% | 0.00% | 7.02% | 51.00% |
| Energy | 0.00% | 0.00% | 0.00% | 46.00% |
| Communication Services | 0.00% | 0.00% | 12.28% | 50.00% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 54.00% |
| Consumer Cyclical | 0.00% | 0.00% | 14.20% | 49.50% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | BMED % Rank | |
|---|---|---|---|---|
| US | 80.25% | 0.09% | 104.41% | 65.50% |
| Non US | 14.69% | 0.00% | 45.40% | 33.50% |
BMED - Expenses
Operational Fees
| BMED Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.85% | 0.08% | 3.13% | 46.53% |
| Management Fee | 0.85% | 0.00% | 1.25% | 85.79% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| BMED Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 0.00% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| BMED Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| BMED Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | N/A | 0.00% | 238.00% | N/A |
BMED - Distributions
Dividend Yield Analysis
| BMED | Category Low | Category High | BMED % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 2.44% | 55.12% |
Dividend Distribution Analysis
| BMED | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Quarterly | Annually |
Net Income Ratio Analysis
| BMED | Category Low | Category High | BMED % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.64% | -2.54% | 1.92% | 80.00% |
Capital Gain Distribution Analysis
| BMED | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually |
BMED - Fund Manager Analysis
Managers
Xiang Liu
Start Date
Tenure
Tenure Rank
Sep 29, 2020
1.67
1.7%
Director of BlackRock since 2016. Prior to joining BlackRock in 2008, Mr. Liu was a Partner and Biotech Analyst at Mehta Partners. Mr. Liu began his investment career in 2000 and has a BS from the University of Science & Technology (China), an MBA from the University of Chicago and a PhD degree in Chemistry from Yale University.
Erin Xie
Start Date
Tenure
Tenure Rank
Sep 29, 2020
1.67
1.7%
Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.
Jeff Lee
Start Date
Tenure
Tenure Rank
Sep 29, 2020
1.67
1.7%
Director of BlackRock since 2011. Mr. Lee began his investment career in 2006 and has a BA from Princeton University
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.26 | 2.12 |
